Pharmaceutical company Bayer announced Thursday that federal regulators have accepted the company’s supplemental New Drug Application for finerenone and provided it with priority review status from the U.S. Food and Drug Administration.
The medication, which goes by the brand name Kerendia, serves as a treatment option for chronic kidney disease that develops in patients with type 1 diabetes.
According to Bayer, clinical trial data backs the supplemental application, demonstrating that finerenone decreased the primary endpoint — specifically the urine albumin-to-creatinine ratio — by approximately 25% from initial measurements over a six-month period when compared to placebo treatment in adult patients diagnosed with the condition.
